Artificial Intelligence (AI) in Pathology- A Summary and Challenges

By Archana Buch & Rohan Kulkarni

Abstract- This bibliographic study covers Artificial Intelligence (AI)theory and its applications from the healthcare field and in particular from the discipline of pathology. This review includes basics of AI, supervised and unsupervised machine learning (ML), various supervised ML algorithms, and their applications in healthcare and pathology. Digital Pathology with Deep Machine Learning is more advantageous over traditional pathology that is based on 'physical slide on a physical microscope'. However, various implementation challenges of cost, data quality, multi-center validation, bias, and regulatory approval issues for AI in clinical practice still remain, which are also described in this study.

Keywords: history of artificial intelligence (AI), AI in healthcare, deep learning (DL) in digital pathology (DP).

GJMR-K Classification: NLMC Code: QY 4

Strictly as per the compliance and regulations of:

Artificial Intelligence (AI) in Pathology– A Summary and Challenges

Archana Buch [α] & Rohan Kulkarni [σ]

Abstract- This bibliographic study covers Artificial Intelligence (AI)theory and its applications from the healthcare field and in particular from the discipline of pathology. This review includes basics of AI, supervised and unsupervised machine learning (ML), various supervised ML algorithms, and their applications in healthcare and pathology. Digital Pathology with Deep Machine Learning is more advantageous over traditional pathology that is based on 'physical slide on a physical microscope'. However, various implementation challenges of cost, data quality, multi-center validation, bias, and regulatory approval issues for AI in clinical practice still remain, which are also described in this study.

Keywords: history of artificial intelligence (AI), AI in healthcare, deep learning (DL) in digital pathology (DP).

I. Introduction

The main objective of this paper is to describe the history of the evolution of Artificial Intelligence over time. The past two decades have shown tremendous progress in the application of artificial intelligence (AI) including in a few medical images based specialties of radiology, dermatology, ophthalmology, and pathology. First, we explore how AI began about 65 years back and its progression in various disciplines including healthcare/medicine and particularly pathology. Second, we review books available on AI in general as well as AI in medicine and in pathology. Next, we define the necessary terms in AI and various AI algorithms that are utilized to get acceptance by the physicians to assist patients in a more efficient fashion. After, we review AI literature pertinent to healthcare and pathology. Finally, the various challenges and barriers AI faces for use in pathological applications are then discussed.

II. AI Theory in Textbooks

In 1955 Artificial intelligence (AI) was termed by McCarthy et al. as the subdivision of computer science in which machine based methodologies were used to make predictions to imitate what human intellect may do in the identical situation.[1] The origin of Digital Pathology (DP) began in 1966, as Prewitt et al. photographed images from a microscopic field from a blood smear and then transformed the information into a matrix of optical density numbers for mechanized image investigation.[2] The AI field is built on statistics and Vapnik provides a more detailed description of the statistical learning theory in his two books.[3, 4] In 2003, Russell and Norig introduced an idea of an intellectual agent that mechanically plans and performs a sequence of activities to attain a goal as a novel form of AI.[5] Good fellow et al.'s comprehensive textbook on the AI is written by some of the most innovative and prolific researchers in the field.[6] Kelleher explains how deep learning is useful in understanding big data and covers methodologies of Autoencoders, Recurrent neural networks, Generative Adversarial Networks, Gradient descent and Backpropagation.[7]

a) AI books in medicine and pathology

There are many excellent textbooks on AI's applications in medicine including note taking, drug development, remote patient monitoring, surgery, laboratory discovery, and healthcare delivery.[8, 9, 10, 11, 12, 13]

In this section our emphasis is on review of the latest textbooks on AI in pathology. Sucacet et al. in *Digital Pathology* (DP) discuss how technology over a decade has seen tremendous growth in its applications. They observe that DP offers the hope of providing pathology consulting and educational services to underserved areas of the world that otherwise would not experience high level of services.[14] In *Artificial Intelligence and Deep Learning in Pathology*, Cohen observes how recent advances in computational algorithms, and the arrival of whole slide imaging (WSI) as a platform for combining AI, are assisting both diagnosis and prognosis by transforming pattern recognition and image interpretation. The book focuses on various AI applications in pathology and covers important topics of WSI for 2D and 3D analysis, principles of image analysis, and deep learning.[15] Holzinger et al. in their book describe why AI and Machine Learning (ML) is very promising in the disciplines of DP, radiology, and dermatology. They observe that in some cases Deep Learning (DL) even exceeds human performance and stress the importance that a human expert regardless should always verify the outcome. The authors cover 'biobanks,' which offer large collections of high quality and well labeled samples as big data is required for training and covering a variety of diseases in different organs.[16]Belciug in his book covers theoretical concepts and practical

Author α: MD, Professor of Pathology, Dr. DY Patil Medical College, Dr. D Y. Patil Vidyapeeth, Pimpri, Pune, India.
Author σ: MBBS, Dr. DY Patil Medical College, Dr. D Y. Patil Vidyapeeth, Pimpri, Pune, India. e-mail: ss1kulkarni@yahoo.com

techniques of AI and its applications in cancer management. The author describes the impactful role of AI during diagnosis and how it can help doctors make better decisions including AI tools to help pathologists identify exact types of cancer and assist surgeons and oncologists. The book discusses over 20 cancer examples in which AI was used and in particular AI algorithms utilized for them.[17]

III. AI Basics

In this section we cover Learning theory, important AI terminology, and algorithms for Machine Learning.

a) Learning theory and machine learning

Vapnik introduces the learning model from examples using three constituents of a) a creator of random vectors, b) a supervisor that yields an output vector for each input vector, and c) a learning machine qualified of applying a set of functions. The next step is the Risk Minimization Problem. So as to find the best obtainable estimate to the supervisor's reply, one should measure the difference between the reply of the supervisor to a specified input and the answer offered by the learning machine.[18] In 2015, Deo's review on ML found that only a few papers out of thousands applying ML algorithms to medical data have contributed meaningfully to clinical care unlike how ML has been impactful in other industries.[19] Cabitza et al. search for 'laboratory medicine/tests' and 'machine learning' terms found 34 papers in Scopus and three in PubMed showing that it is a relatively new area for AI in laboratory medicine/tests.[20]

b) Important AI terminology

In this section we will cover important AI terminology.

a) *Machine learning (ML):* Machine Learning is a discipline of mathematics that combines statistical modeling and computers/machines to learn from available data sets hence its name. ML is classified into categories called 'supervised' and 'unsupervised' learning. ML techniques are widely used in transcribing speech into text, matching news items, and identifying objects in images. In these applications a 'Deep learning' (DL) technique is widely used.

b) *Supervised learning:* In supervised learning the goal is to either predict a known output or target (Y) from input variables (X) using an algorithm to learn the mapping function $[Y= f(X)]$ from the labeled input data to the output. This derived mapping function can then be used for a new input data (X_1) to predict its output variable (Y_1). Supervised learning based models can be of 'classification' or 'regression' types. In the classification case the output variable is a category e.g. disease or lack of disease. Automated interpretation using pattern recognition of a breast X-ray or an EKG to select from a limited set of diagnoses are examples of supervised learning. In a regression problem the output variable is a real continuous value of e.g. temperature or blood pressure. The concept of bias and variance and their relationship with each other are important determinants of the performance of supervised ML models. To obtain a most Generalizable Supervised ML Model requires finding a right balance between bias and variance.

c) *Unsupervised learning:* In unsupervised learning, unlike supervised learning, there is no output prediction variable. Instead, all input data (X) which is unlabeled, the algorithms in this case learn to understand inherent structure from the available input. E.g., an objective could be to look for data patterns to identify novel disease mechanisms.

d) *Semi-supervised learning:* In semi-supervised learning, some of the available data is labeled and the remaining is not. In this type of learning scientists use a combination of supervised and unsupervised methods. LeCun et al. describe various techniques used in ML such as 'Conventional ML' and 'Deep ML.' They discuss limitations of 'Conventional ML' in their ability to process data in their raw form. In contrast 'Representation learning' permits a computer to be served with the data to find the depictions desired for recognition or categorization. 'Deep learning' are 'Representation learning' approaches with numerous stages of representation acquired by creating non-linear sections which convert the representation at one stage into a representation at a higher but at a more abstract level.[21]

e) *Artificial Neural Networks (ANNs):* Similar to a brain which operates through interconnected, complex network of neurons, an Artificial Neural Network has a set of artificial neurons which are layered and connected, with a definite passage way for how information is transmitted through the network. The Artificial Neural Network allows a means of reaching an output that is the outcome of many nondependent phases of computation and weighting.

f) *Convolutional Neural Networks (CNN or ConvNets):* ConvNets are deep, feed forward networks that are easier to train and are generalized better than networks with full connectivity between adjacent layers. CNNs are applicable to use information that come in the shape of numerous arrays such as a colour photo consisting three 2D arrays comprising pixel concentrations in the three colour channels. A CNN is designed with the first few steps being constituted of two types of tiers of convolutional and pooling tiers.[22]

g) *Recurrent Neural Networks (RNN):* RNNs process a given input order of one component at a time while preserving in their concealed parts a 'state vector' which keeps data regarding entire historical components of the arrangement. RNN is appropriate with sequential inputs, such as speech and language. Back propagation is therefore appropriate for training RNNs. Training RNNs can have issues as the back propagated gradients grow/shrink at each step causing them to blow up or become very small.[23]

c) *Algorithms for Supervised ML*

Model building phase of Supervised ML includes splitting of the available data into training and testing sets in order to train the model followed by testing it for validation. The following algorithms are widely used in Supervised ML:

A. *Linear Regression:* Linear regression models find the target by finding the best-fitted "least squares regression line," which has the smallest error sum, amongst the independent continuous variables (features/the cause) and the dependent continuous variables (target/the effect). Aggarwal et al. detail the pitfalls associated with this analysis.[24]

B. *Logistic Regression:* Ranganathan et al. discuss logistic regression examining the relationship of a binary outcome of 'yes/no,' 'alive/dead,' 'success/failure' with one or more predictors being either categorical or continuous. They provide method's limitations in choosing the right predictor variables, avoiding the use of highly correlated variables, restricting the number of variables, and handling continuous input variables.[25]

C. *Convolutional Neural Network or CNN:* Neural Networks attempt to model a neuron which uses certain input features to find and assign appropriate mathematical weights to forecast some output objective. Deep neural network has a sizable number of nodal contacts within its unseen tier and are most appropriate for highly complicated data studies such as images. However, caution is required because of a limitation due to overfitting.

D. *k-Nearest Neighbor or k-NN:* This algorithm is used for data classification and regression tasks of nonparametric clustering. k is defined as the square root of the number of occurrences and its distance from a pre-defined point and classification is based on the number of k neighbors.[26] Being 'distanced based,' they require normalization of features and work best in the presence of a smaller number of input variables but are sensitive to the outliers.

E. *Support Vector Machine or SVM:* The SVM algorithm classifies available data by defining a hyperplane that best differentiates the presence of two groups. The differentiation for the two groups is maximized by growing the space on either side of the hyperplane and the hyperplane enclosed area with the greatest possible distance is then chosen for the evaluation. It finds an onlinear relationship using a kernel function but has tendency for overfitting.[27]

F. *Naive Bayes:* Naive Bayes approach assumes that the features under evaluation are independent of each other. For simple tasks it can produce good results, but in general their performance is inferior to the other ML algorithms.[28]

G. *Decision Tree and Boosted Tree:* A decision tree comprises a root, nodes, branches, and leaves. The node is where the characteristic is examined and the branch is where the result of this examined query is then assigned. The decision tree provides a set of guidelines that defines the passageway from the root all the way to the leaves. Gradient boosting machine uses weak predictors (a Decision tree) that are boosted, which provide a better performing model (a Boosted tree). This method can work with unbalanced data sets but may produce overfitting.[29]

H. *Random Forest or RF:* Breiman provides how RFs are an effective tool in accurate prediction of classifiers and regressors as it avoids overfitting due to the Law of LargeNumbers.[30] However, it might be more time exhausting and less efficient vs. the nonparametric (SVM and k-NN) and parametric (logistic regression) modeling.

IV. AI RESEARCH IN PATHOLOGY

In this section we cover research in topics of origins of image analysis, computational pathologist, machine learning in pathology, Digital Pathology, Convolutional Neural Network in pathology, and other AI in cancer applications.

a) *Origins of image analysis*

Meijer et al. summarized origins of image analysis in the field of clinical pathology related to routine diagnostic cytopathology, histopathology, and research. They distinguished between three different areas of image analysis namely: a) Evaluating morphological features of tissues/cells/nuclei/nucleoli, b) Counting of tissue/cell constituents, and c) Cytometry and configuration recognition. Further they discussed historical significance of Morphometry (quantitative description of geometric features of structures of any dimension), Planimetry (measurement of geometric features of structures in two dimensions), Stereology (quantitative information about geometric features of structures with a test system of lower dimension than the structure itself), and Counting objects techniques in relation to image analysis. Techniques of Cytometry and DNA Cytometry using visible light, coupled with powerful computers have allowed the development of systems for

automatic cell classification based on pattern recognition.[31]

b) Computational pathologist

Beck et al. developed an ML based method for automatically analyzing cancer images and predicting prognosis called the Computational Pathologist (C-Path). Their image processing structure performed an automated, ranked scene subdivision generating measurements in thousands, comprising standard morphometric descriptors of image objects and upper level contextual, relational, and global image characters. The pipeline comprised of three phases. First, their processing steps included a) separating the tissue from its background, b) partitioning the image into smaller regions with a consistent appearance recognized as superpixels, c) finding nuclei inside the superpixels, and d) constructing cytoplasmic and nuclear characters within the superpixels. Next, within every superpixel they estimated the size, shape, intensity, and texture of the superpixel and its neighbors. Afterwards, to create more biologically significant features, they categorized superpixels as either epithelium or stroma. They used an ML based approach of L_1-regularized logistic regression, in which they hand-annotated superpixels from 158 photos and utilized those images to train the classifier. The resultant classifier composed of 31 characters achieved a categorization accuracy of 89% on detained data. The authors using a series of relational characters produced a set of 6,642 features per image. Predicting survival based on the images from patients who were alive 5 years after surgery and also from patients who had died at 5 years after surgery they built the prognostic model. After constructing the model, it then was utilized to a verify set of breast carcinomaphotos which were not part of the model creation to categorize patients as either low or high risk of dying at 5 years. A bootstrap examination on the data set and for each of the 6,642 features the authors obtained a 95% Confidence Interval for the feature's coefficient estimate.[32]

c) Machine learning in pathology

To achieve optimum Supervised Machine Learning Model Rashidi et al. proposed four questions: i) Does the endeavor tackle a necessity?, ii) Is enough data accessible which is appropriate type that scrutinized by clinical specialists?, iii) Which Machine Learning method to utilize?, and iv) Are the enhanced ML simulations appropriate and general enough when used with a new data set? The authors support a balanced approach using clinical trial data merged with real world data to optimize ML training. They recommend that pathologists/laboratorians must be sufficiently familiar with available modeling options in order to make meaningful contributions within the team.[33]

Moxley-Wyles et al. introduce the basics of AI in pathology and discuss the future and challenges for the discipline with focus on surgical pathology instead of cytology. The authors foresee AI's potential to obtain derive novel biological insights by identifying subtle cell changes, which are not recognized by pathologists (using the Haematoxylin and Eosin (H&E) stain) that can predict specific mutations within the cell. Predictions using AI have been proven for Speckle-Type POZ Protein (SPOP) mutation in prostate cancer, *BRAF* in melanoma, and many mutations in lung adenocarcinoma. They observe that with robustly validated AI tools second opinions from other pathologists could become not necessary. The authors expect AI's potential assistance in predicting outcomes of responses to treatments after regulatory approvals. However, in their opinion the use of Artificial Intelligence in diagnostic practice is rare due to some of the limits of Artificial Intelligence including regulatory and validation issues, as well as a high cost.[34]Li et al. used the fluorescence hyperspectral imaging technique to acquire spectral images for the early diagnosis of gastric cancer. They combined DL with spectral-spatial categorization techniques utilizing 120 fresh tissue specimens with an established diagnosis by histopathological assessments. The method was utilized to detect and extract the 'spectral + spatial' characters to create an early cancer diagnosis model. It resulted in the accuracy of 96.5%, specificity of 96%, and sensitivity of 96.3% for non-precancerous lesion, precancerous lesion, and cancer groups.[35]

d) Digital Pathology (DP)

Hartman et al. numerate how DP is more advantageous over traditional pathology based on' physical slide on a physical microscope.' This tool development did benefit from 24 public challenges based publications in specific pathological diagnostic tasks. However, there is a true disconnect between the types of organs studied in these public challenges and the large volume of specimens typically available in clinical practice. Even though disciplines of dermatology and gastrointestinal collect a majority of samples in pathology laboratories, so far there are no pathology based dermatology public challenges while only a few in regards to the gastrointestinal field. This mismatch is the key reason there being a limit on the wider adoption of AI in pathology field.[36]

Niazi et al. have developed the generation of synthetic digital slides that can be used for educational purposes to train future pathologists. Their Conditional Generative Adversarial Networks approach contains two main components of the generator and the discriminator. The generator creates fake stained images, while the discriminator tries to catch them. Their approach of distinguishing between 15 real and 15 synthetic images yielded an accuracy of 47.3% amongst

three pathologists and two image analysts. The authors do see a role for AI in quality assurance by improving the pathologist's performance with the use of intelligent deep learning and AI tools.[37]

DP involving the slide digitization process in some instances does create artifacts that are 'Out-Of-Focus' or OOF. OOF is typically noticed after a careful review which requires a whole-slide rescanning, as the manual screening for OOF affecting only parts of a slide isnot feasible. Kohlberger et al. developed a ConvFocus using a refined semi-synthetic OOF information production process and was assessed using seven slides covering three dissimilar tissue and three dissimilar stain types and then was digitized. For 514 separate regions representing 37.7K 35 µm × 35 µm image patches, and 21 digitized "z-stack" Whole Slide Images containing known Out-Of-Focus patterns, ConvFocus scored Spearman rank coefficients of 0.81 and 0.94 on two separate scanners, and it replicated the expected Out-Of-Focus patterns from z-stack scanning. More importantly the authors observed a decrease in the accuracy with increasing OOF.[38]

Hartman et al. investigated a US healthcare organization with 20+ hospitals, 500 outpatient sites, international affiliations of one hospital in Italy and a lab in China. The organization employs 100+ pathologists, does consultations by telepathology from the Chinese lab, and uses Digitized Pathology scanned over 40,000 slides. Their conclusion for attainment of successful DP is performing a combination of pre-imaging adjustments, integrated software, and post-imaging evaluations.[39] Parwani observed that to attain DP in a lab requires an essential alteration in how tissue is handled and the workflow is harmonized, and the laboratory has attained a digital workflow. It is more than making the workflow to digital and acquiring WSI scanners. He numerates a key advantage the digital workflow provides of reduction in errors in DP and obtaining a second opinion.[40]

In DP problems of color variations do arise in tissue appearance due to the disparity in preparation of tissues, difference in stain reactivity between different batches and different manufacturers, user and/or protocol dissimilarity, and the use of scanners from diverse vendors. Khan et al. present a novel preprocessing approach to histopathology image stain normalization using representation derived from color deconvolution based on non-linear mapping of a source image to a target image. A method of color deconvolution obtains stain intensity values when the stain matrix, which describes how the colour is changed by the stain intensity is made available. Instead of using the standard stain matrices, which might be unsuitable for a specified image, they recommend the utilization of a colour based classifier incorporating a new stain colour descriptor to compute image explicit stain matrix.[41]

Janowczyk et al. developed a tutorial on focusing on the critical components needed by DP experts in automating tasks of grading or investigating clinical hypothesis of prognosis prediction. The authors examined seven use cases of (i) nuclei segmentation, (ii) epithelium segmentation, (iii) tubule segmentation, (iv) lymphocyte detection, (v) mitosis detection, (vi) IDC detection, and (vii) lymphoma classification, and demonstrated how DL can be applied to the most common image analysis tasks in DP using open source framework Caffe. They further subdivided the seven tasks into three categories of detection (mitotic events, lymphocytes), segmentation (nuclei, epithelium, tubules), and tissue classification (IDC, lymphoma sub-types), as the approaches used are similar within each analysis category. With over 1200 DP images used during evaluation produced the following: (i) nuclei subdivision with F score of 0.83, (ii) epithelium subdivision with F score of 0.84, (iii) tubule subdivision with F score of 0.83, (iv) lymphocyte detection with F score of 0.90, (v) mitosis recognition with F score of 0.53, (vi) invasive ductal cancer recognition with F score of 0.77, and (vii) lymphoma categorization with categorization accuracy of 0.97. In many of these cases the results are excellent versus seen from the modern feature-based categorization approaches.[42]

To guide surgical decisions further, intraoperative frozen sections are useful for rapid pathology-based diagnosis. However, the quality of frozen sections is lower compared to formalin fixed paraffin embedded tissue[43] and that they must be diagnosed within 20 min of receipt. In current clinical practice, thyroid nodule surgeries are the most common in requiring intraoperative consultations. However, using traditional approach the sensitivity for diagnosing thyroid nodules from frozen sections is around 75%.[44] Li et al. investigated for the first time if a 'patch-based diagnostic system' with DL methodology can diagnose thyroid nodules from intraoperative frozen sections. They approached the problem as a three-category classification problem of benign, uncertain, and malignant classes. In order to reduce the overall time cost, they applied tissue localization first in the whole slide diagnosis to locate thyroid tissue regions. This rule-based system considered the conservative diagnosis manner of the practical thyroid frozen section diagnosis. Their computerized diagnostic technique demonstrated a precision of malignant and benign of thyroid nodules of 96.7% and, 95.3% respectively, and 100% sensitivity for the unsure category. Moreover, the methodology resulted in diagnosis of a typical Whole Slide Image in less than one min.[45]Paeng's presentation covers limitations of pathology and relative advantages of DP of reproducibility, accuracy, and workload reduction. Key applications of DP are a) Tumor proliferation score prediction – breast resection, and b) Gleason score prediction – prostate biopsy. The

author's method scored the best in Tumor Proliferation Assessment Challenge. He achieved Gleason score prediction of 83% for core-level performance and discussed overcoming: how to handle gigapixel images, how to handle quality variation between slides, and how to handle ambiguous ground-truth.[46]

e) Convolutional Neural Network (CNN) in pathology

Hegde et al. for histopathology images introduced 'SMILY' (Similar Medical Images Like Yours) which is a DL based reverse image search tool. Their tool follows the steps of: a) Create a database of image patches and a numerical portrayal of each patch's image fillings called the embedding, b) Calculate the embedding utilizing a CNN, c) SMILY calculates the embedding of the selected query image and matches it in a proficient manner with those in the database, and in the last step d) SMILY yields the k most similar patches, where k is customizable. To create the database the authors used images from TCGA with the evaluations utilizing127K image patches from 45 slides while the question set included 22.5K patches from additional 15 slides. The CNN algorithm, instead of using large, pixel-annotated datasets of histopathology images, was trained using a dataset of images of people, animals, and manmade and natural objects. In the assessment of prostate specimens for finding similar histologic features, SMILY scored 62.1% on average which is, considerably higher than the random search results score of 26.8% with p-value< 0.001. SMILY's score for histologic feature match, when queried from multiple organs, was appreciably higher than random with the score of 57.8% vs. 18.3% with p-value < 0.001.The authors claim that SMILY can be used as a general purpose tool in multiple applications of diagnosis, research, and education even though it will have lower accuracy than an application specific tool.[47]

f) AI in cancer applications

AI in breast cancer: Stålhammar et al. for prognostic and predictive value categorized breast cancers by using four gene expressions 'Luminal A,' 'Luminal B,' 'HER2-enriched,' and 'Basal-like.' The authors examined 3 cohorts of main breast carcinoma specimens totaling 436 (up to 28 years of survival) and scored them for ER, PR, HER2, and Ki67 rank by Digital Image Analysis (DIA) and manually. DIA approach beat manual scoring in both sensitivity and specificity for the Luminal B subtype, and achieved slightly superior concordance and Cohen's κ agreement in reference with PAM50 gene expression assays. The manual biomarker and DIA approaches were close in comparison of each other for Cox regression hazard ratios. In addition DIA faired superior in terms of Spearman's rank-order correlations, and prognostic value of Ki67 scores in terms of likelihood ratio thus adding appreciably more prognostic information to the manual scores. The authors

concluded that overall the DIA approach was clearly a better substitute to the method of manual biomarker scoring.[48] A manual process identifying the existence and degree of breast carcinoma by a pathologist is serious for patient administration for tumor staging, including an assessment of treatment response, but it is subject to variability between inter- and intra-reader. As a decision support tool any computerized technique needs to be robust to data acquisition from different sources, different scanners, and different staining/cutting approaches. Cruz-Roa et al.'s CNN approach trained the classifier using 400 exemplars from various sites and using TCGA data to validate it with 200 cases. Their approach attained a Dice coefficient of 75.9%, a PPV of 71.6%, and a NPV or of 96.8% regarding the evaluation for pixel-by-pixel in reference with manually annotated regions of invasive ductal carcinoma.[49]

Autoencoder (AE) use in breast cancer: An AE can be described as an ANN with a symmetric construction in which middle tiers encode the entered data and then aim to construct a form of its input onto the yield tier and avoids using a direct copy of the data along with the network.[50] Macías-García et al. developed a structure to process DNA methylation to obtain meaningful data from pertinent genes regarding breast cancer recurrence and tested it using The Cancer Genome Atlas (TCGA) data portal. The method is based on AEs to preprocess DNA methylation and generate AE features to characterize breast cancer recurrence and demonstrated how it improved recurrence prediction.[51]

AI in cervical cancer: Out of half million annual cervical cancer cases in the world about 80% occur in low and middle income nations. Hu et al. followed over 9,000 women ages 18 to 94 from Costa Rica over period of seven years from 1993 to 2000 identifying cancers up to 18 years. They developed a DL based visual evaluation algorithm based on digitized cervical images taken with a fixed focus camera (cervicography), which did automatically identify cervical precancer or cancer. The DL method recognized cumulative precancer and cancer cases with higher AUC of 0.91compared to the original cervigram interpretation with AUC of 0.69 or conventional cytology with AUC of 0.71. The authors therefore recommend use of automated visual evaluation of cervical images from contemporary digital cameras.[52]

AI in prostate cancer: Ström et al. work noticed the high intra/inter-observer variability in grading resulting in either under or over treatment of prostate carcinoma. To overcome this issue the authors developed an AI method for prostate cancer detection/localization, and Gleason grading. They digitized 6,682 slides from biopsies of 976 randomly selected Swedes aged 50-69 and another 271 slides from 93 men from outside the original study to train deep neural networks. The

resulting networks were tested with independent 1,631 biopsies from 246 men from STHLM3 for the presence, extent, and Gleason grade of malignant tissue and an exterior data from 73 men of 330 biopsies. They also compare drating performance by 23 pathology experts on grading 87 biopsies. The AI networks attained an AUC of 0·997 for differentiating between benign and malignant biopsy cores on the independent dataset and 0·986 on the external verification data between benign and malignant. The correlation found between carcinoma length predicted by the Artificial Intelligence networks and given by the pathology experts was 0·96 for the impartial data and 0·87 for the external verification dataset. The AI methodology for allotting Gleason grades attained a mean pairwise kappa of 0·62which was within the range of values for the pathology experts of 0·60-0·73. The authors recommend using the AI approach resulting in reduction of the evaluation of benign biopsies and automating the work of determining cancer length in the cases of positive biopsy cores. This AI approach by standardizing grading can be utilized as a second opinion in cancer assessment.[53]

AI in stomach and colon cancer: Iizuka et al. in their study utilized biopsy histopathology WSIs of stomach and colon trained CNNs and RNNs to classify them into adenocarcinoma, adenoma, and non-neoplastic. They gathered datasets of stomach and colon consisting of 4,128 and 4,036 WSIs, respectively which were then manually annotated by pathologists. The authors using millions of tiles extracted from the WSIs then trained a CNN based on the Inception-V3 architecture for each organ to categorize a tile into one of the three classification tags. Next they summed the projections from all the tiles in the WSI to acquire a final categorization using two approaches of a RNN and a Max Pooling. The models were successfully evaluated on three independent test sets each and achieved Area Under the Curves (AUCs) for gastric adenocarcinoma and adenoma was 0.97 and 0.99 respectively, and for colonic adenocarcinoma and adenoma of 0.96 and 0.99 respectively. Further they evaluated the stomach model versus a collection of pathology experts and medical scholars that were not part of labeling the teaching set utilizing an investigation set of 45 images (15 WSI of adenoma, 15 of adenocarcinoma, and 15 of non-neoplastic lesions). The categorization time for Whole Slide Image using the educated model ranged from 5-30 seconds. The average accuracy of diagnoses achieved by pathologists was 85.9%, medical school students was 41.2%, while the stomach model achieved an accuracy of 95.6% in a 30 sec assessment.[54]

AI in lung cancer: Kriegsmann et al.'s evaluation of CNNs included the classification of the very usual lung carcinoma subtypes of pulmonary adenocarcinoma (ADC), pulmonary squamous cell carcinoma (SqCC),

and small-cell lung cancer (SCLC). To validate the appropriateness of the outcomes, skeletal muscle was also integrated in the investigation, as histologically the difference between skeletal muscle and the three tumor entities is unambiguous. They assembled a group of 80 ADC, 80 SqCC, 80 SCLC, and 30 skeletal muscle specimens. TheInceptionV3, VGG16, and Inception ResNetV2 architectures were qualified to categorize the four entities of interest.InceptionV3 based on the CNN model produced the highest classification accuracy and hence was used for the classification of the test set. The final model received an image patch categorization accuracy of 88% in the training as well as in the verification set. In the test set they achieved image patch and patient-based CNN classification results of 95% and 100%.[55] To predict carcinoma in WSIs, Kanavati et al. trained a deep learning CNN founded on the EfficientNet-B3 design, using transfer learning and weakly-supervised learning to calculate carcinoma using a training dataset of 3,554 WSIs from a sole medical establishment. The model was then applied to four independent test sets from distinct hospitals in order to validate its generalization on unseen data. The authors obtained excellent results that did show differentiation amongst lung cancer and non-neoplastic with an elevated Receiver Operator Curve based AUCs on impartial investigation of four sets of 0.98, 0.97, 0.99, and 0.98, respectively. Out of two methodologies to train the simulations of 'fully supervised learning' and 'weakly supervised learning,' the last performed always superior with an improvement of 0.05 in the AUC on the experiment sets.[56]

V. AI - Regulation

The FDA's vision is that with suitable regulatory oversight, Software as a Medical Device (SaMD) based on AI-ML will deliver safe and effective software functionality that will be able to improve the quality of patient care. Their guidance for software modifications focuses on the risk to patients resulting from the software change. For a traditional application three classes of software alterations that might necessitate a premarket submission include: a) a change that introduces a novel risk or changes an existing risk that can produce significant harm, b) an alteration to risk controls to avoid substantial harm, and c) a modification that considerably affects clinical functionality of the device. For SaMD, any modifications would require a premarket submission to the FDA when the AI/ML software changes significantly, the alteration is to the device's envisioned use, or the alteration introduces a key change to its algorithm. The FDA to date has approved several AI/ML-based SaMD algorithms that are locked before marketing and algorithm modifications will possibly require an FDA pre-market assessment for the modifications beyond the initial approval. However,

the SaMD has the capability to constantly learn, as the alteration or modification to the algorithm is recognized after the SaMD has learned from real world experience might provide a significantly dissimilar output in contrast to the output originally approved for a specified set of inputs. Therefore, the AI/ML tools require a new, Total Product Life Cycle (TPLC) regulatory approach.[57]

VI. AI – Issues to be Resolved

Over the last 100 years both The Covid19 and The Spanish Flu pandemics have shown their disproportionate impacts on patients of low income and racial minorities. A combination of diagnostics bias and sample bias have been the culprit for the global healthcare disparities. Evans argues that present diagnostic tools often fail patients who do not fit the prospects of the majority.[58] Even though there is an active effort to involve females in clinical study samples there are many treatment and drug advices that are founded on findings taken from the samples of Caucasian males. The author proposes, going forward, to decode the present and reshape existing practices before implementing AI to avoid existing biases and further increasing health disparities.[59]

Colling et al. propose a UK-wide strategy for AI and DP. If the requirements of proper slide image management software, integrated reporting systems, improved scanning speeds, and high-quality images for DP systems are achieved then it will provide time and cost saving benefits over the traditional microscope based pathology approach and reduce problem of inter-observer variation. The successful introduction of AI and DP tools to the healthcare system will need proper regulatory approved and evidence based validation, and a lowering of the resistance to collaborate between academic and industry developers.[60] Robertson et al.'s work discusses the limitations of deep learning as it works well in supervised learning but not for unsupervised learning. The deep learning approach is not suitable for the discovery of novel biomarkers, as it being an unsupervised learning problem. If the model is educated only by means of images attained from imaging equipment from a single merchant then it may fail to react acceptably to images acquired from the equipment of another merchant. They observe the challenges to having a full digital workflow, a must for deep learning, due to the high costs and the dependence on solid IT support systems.[61] Typically, training of DL models requires many of annotated samples that belong to dissimilar categories. However, in reality it can be hard to collect a balanced dataset for training because of the fact that certain ailments have a low prevalence causing problem of data. Studies have shown that many models that perform well on balanced datasets do not when it comes to their imbalanced counterparts.[62] Most of medical image datasets possess this imbalance problem. One-class classification, which emphases on learning a model using examples from only a single given class, is used as an approach to overcome the problem of imbalance. Gao et al. proposed a novel method which allows DL models to leverage the concept of imaging complexity to optimally learn single-class-relevant inherent imaging features. They then compared the effects of perturbing operations used on images to realize imaging intricacy to boost feature learning, and allowing their method outperforming four advanced methods.[63]

Tizhoosh et al. explore problems that must be solved in order to exploit opportunities for the AI promises in computational pathology. The challenges discussed include: i) Lack of labeled or annotated data can be overcome by using active learning applied to labeling with public datasets, ii) Pervasive variability: infinite number of patterns due to presence of several tissue types (connective tissue, nervous tissue, epithelium, and muscle) required by AI algorithms to be learned, iii) Non-Boolean nature of diagnostic tasks as binary language of 'yes' or 'no' can be possible in only easy pathological cases but is rarity in the clinical practice, iv) Dimensionality obstacle: Use of "Patching" (divide an image into small tiles) as WSI sizes typically are larger than 50Kx 50K pixels, v) Turing test dilemma: A machine can be as intelligent as a human and Turing test for DP is explicitly not known, vi) Uni-task orientation of weak artificial intelligence as Deep ANNs are designed to perform only one task requiring independently training multiple AIs for tasks of classification, segmentation, and search, vii) Affordability of required computational expenses for adoption of DP is a challenge due to high costs of acquisition and storage of gigapixel histopathological scans, viii) Adversarial attacks (Targeted manipulation of a very small number of pixels inside an image can mislead the network) as negligible presence of artifacts produce misdiagnosis, ix) Lack of transparency and interpretability which is not acceptable to the physicians as there is a lack of explanation on why AI made a specific decision in reference to histopathology scans, and x) Realism of AI as the pathology community has yet to buy in fully due to its issues related to ease of use, financial return, and trust. The authors describe multiple opportunities of: a) Deep features – Pretraining is better using Transfer learning instead of training a new network from scratch, b) Handcrafted features (such as gland shape and nuclear size)– Do not forget computer vision as it can be applied in DP to attain high identification accuracies, c) Generative frameworks: Learning to see and not judge as Generative models, focus on acquiring to reproduce data instead of making any decision such as pulmonary disease categorization and for functional MRI analysis, d) Unsupervised learning: When we do not need annotations in self-organizing plots and hierarchical clustering, and

effectively combine them in the workflow of usual practice of pathology as annotating images is not portion of the everyday work of pathology experts, e) Virtual peer review – Placing the pathologist in the central to both algorithm development and execution: Algorithms extract reliable information from proven archived diagnosed cases similar to the relevant features of the patient, that are diagnosed and treated by other physicians; Comparing for example diagnosis of patient's cervix biopsy to a prior Pap test assessment for real-time cytologic-histopathologic correlation, f) Automation with AI can assist with case triage by performing laborious tasks for example of screening for easily identifiable cancer types or counting mitoses, and with simplification of complex tasks (e.g., triaging biopsies which require immediate action and ordering suitable stains upfront when specified); AI algorithms have attained sensitivity above 92% for breast cancer recognition, g) Re-birth of the hematoxylin and eosin image: combination of computational pathology and emerging technologies of multiplexing and three-dimensional imaging allows analysis of individual pixels of pathological images to understand diagnostic, and theoretically available prognostic information, h) Making data science accessible to pathologists will enhance their accuracy with the use of AI tools to generate/analyze big image data.[64]

To integrate AI based algorithms into the workflow of pathologists, Jiang et al. outlined and discussed various challenges facing their implementation in pathology. The challenges include: i) Validation: AI models are typically established on small-scale data and images from single-center and therefore they need to be sufficiently validated using multi-institutional data before clinical adoption, ii) Interpretability: DL-based AI methods are rightfully perceived as 'black-box' methods due to their lack of interpretability which is an obstacle towards the clinical adoption by doctors, iii) Computing system: Histopathological photo file dimensions are typically 1,000x of an X-ray and 100x of a CT image files requiring powerful computing and storage, and bandwidth to transmit gigapixel-sized images, iv) Attitude of pathologists: Due to the lack of AI based model's interpretability, pathologists are afraid of the change in workflow and worry about how to describe the evidence from AI in the diagnosis report, v) Attitude of clinicians and patients: In order to have both clinicians and patients have trust, AI based diagnostic and prognostic/predictive assays ought to have a high accuracy, and vi) Regulators: The clinical adoption of AI digital pathology needs approval by regulatory agencies and the lack of interpretability limits the approval.[65] Samek et al. present two methods that describe predictions of deep learning models to overcome DL's black box approach. The first method which computes the sensitivity of the prediction with respect to changes

in the input and the second approach meaningfully decomposes the decision in terms of the input variables.[66] Some of problems that need to be overcome to achieve the progress of DP and ML in their daily usage in pathology practice are: a) Make interfaces user friendly which currently are not, b) Require a single image format instead of current existence of several proprietary image formats, c) Overcome issue of the large image file sizes using technological advances in storing, and d) Enhance interactions between AI experts and pathologists.[67]

AI machine learning model development, a multi-step process, includes important technical, regulatory, and clinical barriers. The model should overcome these barriers, which collectively define a "translation gap," in order to being accepted in a real world. The translation gap in digital pathology includes a variability caused by the manual nature of the tissue acquisition process and histopathology slide preparation, differences introduced during tissue sampling, tissue fixation, sectioning, and staining. During model development and validation these variations must be accounted for in order to achieve its widespread adoption. Also, since DP is relatively immature, at present only two manufacturers have received FDA approval to market digital pathology systems for primary diagnosis.[68, 69] Similarly Steiner et al. discuss how the low penetration of digital pathology has negatively affected integration of AI into pathologist's diagnostic workflow and validation of algorithms in live clinical settings.[70]

VII. CONCLUSION

Artificial Intelligence (AI) has come a long way over the last 65 years. Over the last two decades research in AI has gained traction in healthcare and it is now being applied across many medical subspecialties of dermatology, radiology, and pathology. A nationwide or global strategy for AI and Digital Pathology (DP) will be necessary in order to be used for automated diagnosis, triaging cases for improved workflow, or deriving novel insights for pathologists. If DP system's requirements of proper slide image management software, integrated reporting systems, improved scanning speeds, and high-quality images, are achieved then it will provide time and cost saving benefits over the traditional microscope based pathology approach, offer a second opinion, and in addition it will reduce the problem of inter-observer variation. However, AI approaches including deep learning do face rightful criticism, as their internals to make decisions by design are not known and hence will require legal and regulatory issues worked out to reap the possible benefits. The successful introduction of AI and DP tools to the healthcare system will need proper regulatory approved evidence based validation, and

lowering of the resistance to collaboration between academic and industry developers.

References Références Referencias

1. McCarthy J, Minsky ML, Shannon CE. A proposal for the Dartmouth summer research project on artificial intelligence - August 31, 1955. Ai Mag. 2006; 27(4):12–4.

2. Prewitt J., Mendelsohn M. "The analysis of cell images." Ann N Y Acad Sci. 1966; 128(3):1035–53. 10.1111/j.1749-6632.1965.tb11715.x. https://nyas pubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749 -6632.1965.tb11715.x.

3. Vapnik V. *The Nature of Statistical Learning Theory.* Second edition. Springer-Verlag, 1995.

4. Vapnik V. *Statistical Learning Theory*. Wiley, 1998.

5. Russell S., Norvig P. *Artificial intelligence: a modern approach.* Upper Saddle River: Prentice Hall, 2003.

6. Goodfellow I., Bengio Y., et al. *Deep Learning (Adaptive Computation and Machine Learning series) Illustrated Edition.* The MIT Press, 2016.

7. Kelleher J. *Deep Learning (The MIT Press Essential Knowledge series) Paperback – Illustrated,* The MIT Press, 2019.

8. Topol E. *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again.* Basic Books, 2019.

9. Mahajan P. *Artificial Intelligence in Healthcare: AI, Machine Learning, and Deep and Intelligent Medicine Simplified for Everyone*. 2ⁿᵈ Edition, MedMantra, 2019.

10. Bohr A., Memarzadeh K. *Artificial Intelligence in Healthcare*. 1ˢᵗ Edition, Academic Press, 2020.

11. Chang A. *Intelligence-Based Medicine: Artificial Intelligence and Human Cognition in Clinical Medicine and Healthcare.* 1ˢᵗ Edition, Academic Press, 2020.

12. Lawry T. *AI in Health: A Leader's Guide to Winning in the New Age of Intelligent Health Systems (HIMSS Book Series)*. 1ˢᵗ Edition, CRC Press, 2020

13. Xing L., Giger M., Min J. *Artificial Intelligence in Medicine: Technical Basis and Clinical Applications.* 1st Edition*,* Academic Press, 2020.

14. Sucaet Y., Waelput W. *Digital Pathology (Springer Briefs in Computer Science).* Springer, 2014.

15. Cohen S. *Artificial Intelligence and Deep Learning in Pathology E-Book.* 1ˢᵗ Edition*,* Elsevier, 2020

16. Holzinger A., Goebel R., et al. *Artificial Intelligence and Machine Learning for Digital Pathology: State-of-the-Art and Future Challenges (Lecture Notes in Computer Science Book 12090).* 1ˢᵗ Edition, Springer, 2020.

17. Belciug S. *Artificial Intelligence in Cancer: Diagnostic to Tailored Treatment.* 1ˢᵗ Edition, Academic Press, 2020.

18. Vapnik V. "An overview of statistical learning theory." IEEE Trans Neural Netw. 1999; 10:988–999. http://citeseerx.ist.psu.edu/viewdoc/download?doi= 10.1.1.332.356&rep=rep1&type=pdf.

19. Deo R. "Machine Learning in Medicine." *Circulation*. 2015; 132(20): 1920-1930. doi:10.1161/ CIRCULATIONAHA.115.001593.

20. Cabitza F., Banfi G. "Machine learning in laboratory medicine: waiting for the flood?" Clin Chem Lab Med. 2018 Mar 28; 56(4): 516-524. doi: 10.1515/ cclm-2017-0287. PMID: 29055936.

21. LeCun Y., Bengio Y., Hinton G. "Deep learning." Nature. 2015; 521(7553):436–444.

22. LeCun, Y., Bottou, L., Bengio, Y., et al. "Gradient-based learning applied to document recognition." Proc. IEEE 86, 2278–2324 (1998).

23. Hochreiter S., Schmidhuber J. "Long short-term memory." Neural Comput. 9, 1735–1780 (1997).

24. Aggarwal R., Ranganathan P. "Common pitfalls in statistical analysis: Linear regression analysis." *Perspect Clin Res*. 2017; 8(2):100-102. doi:10.4103/ 2229-3485.203040.

25. Ranganathan P., Pramesh C., Aggarwal R. "Common pitfalls in statistical analysis: Logistic regression." *Perspect Clin Res*. 2017; 8(3):148-151. doi:10.4103/picr.PICR_87_17.

26. Hall P., Park B., Samworth R. "Choice of neighbor order in nearest-neighbor classification." Annals of Statistics. 2008; 36:2135–2152. DOI: 10.1214/07-AOS537.

27. Hearst M., Dumais S., Osuna E. et al. "Support vector machines," in *IEEE Intelligent Systems and their Applications*, vol. 13, no. 4, pp. 18-28, July-Aug. 1998, doi: 10.1109/5254.708428.

28. George J., Langley P. "Estimating continuous distributions in Bayesian classifiers." Paper presented at: Eleventh Conference on Uncertainty in Artificial Intelligence; August 18–20, 1995; Montréal, Qué, Canada.

29. Elith J., Leathwick J., Hastie T. "A working guide to boosted regression trees." J Anim Ecol. 2008 Jul; 77(4): 802-13. doi: 10.1111/j.1365-2656.2008. 01390.x. Epub 2008 Apr 8. PMID: 18397250.

30. Breiman L. "Random forests." Mach Learn. 2001; 45:5–32.

31. Meijer G., Beliën J., van Diest P., et al. "Origins of ... image analysis in clinical pathology." *J Clin Pathol*. 1997; 50(5):365-370. doi:10.1136/jcp.50.5.365.

32. Beck A., Sangoi A., Leung S. et al. "Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival." Science Translational Medicine 09 Nov 2011: Vol. 3, Issue 108, pp. 108ra113 DOI: 10.1126/scitranslmed. 3002564.

33. Rashidi H., Tran N., Betts E., et al. Artificial "Intelligence and Machine Learning in Pathology: The Present Landscape of Supervised

Methods." *Acad Pathol*. 2019; 6:23742895 19873088. Published 2019 Sep 3. doi:10.1177/ 2374289519873088.

34. Moxley-Wyles B., Colling R., Verrill C. "Artificial intelligence in pathology: an overview." Diagnostic Histopathology, Volume 26, Issue 11, 2020, Pages 513-520, ISSN 1756-2317. https://doi.org/10.1016/ j.mpdhp.2020.08.004.

35. Li Y., Deng L., Yang X., et al. "Early diagnosis of gastric cancer based on deep learning combined with the spectral-spatial classification method." *Biomed Opt Express*. 2019; 10(10):4999-5014. Published 2019 Sep 9. doi:10.1364/ BOE.10.004999.

36. Hartman D., Van Der Laak J., Gurcan M., et al. "Value of Public Challenges for the Development of Pathology Deep Learning Algorithms." J Pathol Inform. 2020 Feb 26; 11:7. doi: 10.4103/ jpi.jpi_64_19. PMID: 32318315; PMCID: PMC7147520.

37. Niazi M., Parwani A., Gurcan M. "Digital pathology and artificial intelligence." Lancet Oncol. 2019 May; 20(5):e253-e261. doi: 10.1016/S1470-2045(19)3015 4-8. PMID: 31044723.

38. Kohlberger T., Liu Y., Moran M., et al. "Whole-Slide Image Focus Quality: Automatic Assessment and Impact on AI Cancer Detection." *J Pathol Inform*. 2019; 10:39. Published 2019 Dec 12. doi:10.4103/jpi.jpi_11_19.

39. Hartman D., Pantanowitz L., McHugh J., et al. "Enterprise Implementation of Digital Pathology: Feasibility, Challenges, and Opportunities." *J Digit Imaging*. 2017;30(5):555-560. doi:10.1007/s10278-017-9946-9

40. Parwani, A. "Next generation diagnostic pathology: use of digital pathology and artificial intelligence tools to augment a pathological diagnosis." *Diagn Pathol* 14, 138 (2019). https://doi.org/10.1186/ s13000-019-0921-2.

41. Khan A., Rajpoot N., Treanor D., et al. "A nonlinear mapping approach to stain normalization in digital histopathology images using image-specific color deconvolution." IEEE Trans Biomed Eng. 2014 Jun; 61(6):1729-38. doi: 10.1109/TBME.2014.2303294. PMID: 24845283.

42. Janowczyk A., Madabhushi A. "Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases." *J Pathol Inform*. 2016; 7:29. Published 2016 Jul 26. doi:10.4103/ 2153-3539.186902.

43. Novis D., Gephardt G., Zarbo R. "Interinstitutional comparison of frozen section consultation in small hospitals: a college of American pathologists Q-probes study of 18532 frozen section consultation diagnoses in 233 small hospitals." Arch Pathol Lab Med, 120 (12) (1996), p. 1087. https://search. proquest.com/openview/72a14d7423df2f7ce34028c 1b4e1f74f/1?pq-origsite=gscholar&cbl=42082.

44. Kahmke R., Lee W., Puscas L., et al. "Utility of intraoperative frozen sections during thyroid surgery." Int J Otolaryngol (2013), 10.1155/ 2013/496138.

45. Li Y., Chen P., Li Z., et al. "Rule-based automatic diagnosis of thyroid nodules from intraoperative frozen sections using deep learning." Artificial Intelligence in Medicine, Volume 108, 2020, 101918. ISSN 0933-3657. https://doi.org/10.1016/j.artmed. 2020.101918.

46. Paeng K. (2017). *ARTIFICIAL INTELLIGENCE FOR DIGITAL PATHOLOGY* [PowerPoint presentation]. GPU Technology Conference, San Jose, CA, USA. https://on-demand.gputechconf.com/gtc/2017/ presentation/s7677-paeng-kyunghyun-artificial-intelligence-for-digital-pathology.pdf.

47. Hegde, N., Hipp, J.D., Liu, Y. et al. "Similar image search for histopathology: SMILY." *npj Digit. Med.* 2, 56 (2019). https://doi.org/10.1038/s41746-019-0131-z.

48. Stålhammar G., Fuentes M., Lippert M., et al. "Digital image analysis outperforms manual biomarker assessment in breast cancer." Mod Pathol. 2016 Apr; 29(4): 318-29. doi: 10.1038/modpathol.2016.34. Epub 2016 Feb 26. PMID: 26916072.

49. Cruz-Roa A., Gilmore H., Basavanhally A., et al. "Accurate and reproducible invasive breast cancer detection in whole-slide images: A Deep Learning approach for quantifying tumor extent." *Sci Rep*. 2017; 7:46450. Published 2017 Apr 18. doi:10.1038/srep46450.

50. Charte D., Charte F., García S., et al. "A practical tutorial on autoencoders for nonlinear feature fusion: Taxonomy, models, software and guidelines." Information Fusion, Volume 44, 2018, Pages 78-96. ISSN 1566-2535. https://doi.org/10.1016/j.inffus. 2017.12.007.

51. Macías-García L., Martínez-Ballesteros M., Luna-Romera J., et al. "Autoencoded DNA methylation data to predict breast cancer recurrence: Machine learning models and gene-weight significance." Artificial Intelligence in Medicine, Volume 110, 2020,101976. ISSN 0933-3657. https://doi.org/ 10.1016/j.artmed.2020.101976.

52. Hu L., Bell D., Antani S., et al. "An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening." *J Natl Cancer Inst*. 2019; 111(9): 923-932. doi:10.1093/ jnci/djy225.

53. Ström P., Kartasalo K., Olsson H., et al. "Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study." Lancet Oncol. 2020 Feb;21(2):222-232. doi: 10.1016/S1470-2045(19)30738-7. Epub 2020 Jan 8.

Erratum in: Lancet Oncol. 2020 Feb; 21(2):e70. PMID: 31926806.

54. Iizuka O., Kanavati, F., Kato K., et al. "Deep Learning Models for Histopathological Classification of Gastric and Colonic Epithelial Tumours." *Sci Rep* 10, 1504 (2020). https://doi.org/10.1038/s41598-020-58467-9.

55. Kriegsmann M., Haag C., Weis C., et al. "Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer." *Cancers* 2020, *12*(6), 1604. https://doi.org/10.3390/cancers12061604.

56. Kanavati F., Toyokawa G., Momosaki S., et al. "Weakly-supervised learning for lung carcinoma classification using deep learning." *Sci Rep* 10, 9297 (2020). https://doi.org/10.1038/s41598-020-66333-x.

57. US Food and Drug Administration. "Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) – Discussion Paper and Request for Feedback." 2019. https://www.fda.gov/media/122535/download.

58. Evans M. "Covid's Color Line — Infectious Disease, Inequity, and Racial Justice" N Engl J Med, 383 (July (5)) (2020), pp. 408-410, 10.1056/NEJMp2019445.

59. Straw I., "The automation of bias in medical Artificial Intelligence (AI): Decoding the past to create a better future." Artificial Intelligence in Medicine, Volume 110, 2020, 101965. ISSN 0933-3657. https://doi.org/10.1016/j.artmed.2020.101965.

60. Colling R., Pitman H., Oien K., et al. "Artificial intelligence in digital pathology: a roadmap to routine use in clinical practice." J Pathol. 2019 Oct;249(2):143-150. doi: 10.1002/path.5310. Epub 2019 Jul 18. PMID: 31144302.

61. Robertson S., Azizpour H., Smith K., et al. "Digital image analysis in breast pathology-from image processing techniques to artificial intelligence." Transl Res. 2018 Apr; 194:19-35. doi: 10.1016/j.trsl.2017.10.010. Epub 2017 Nov 7. PMID: 29175265.

62. Leevy J., Khoshgoftaar T., Bauder R., et al. "A survey on addressing high-class imbalance in big data." J Big Data, 5 (2018), p. 42. https://link.springer.com/article/10.1186/s40537-018-0151-6.

63. Gao L., Zhang L., Liu C., et al. "Handling imbalanced medical image data: A deep-learning-based one-class classification approach." Artificial Intelligence in Medicine, Volume 108, 2020, 101935. ISSN 0933-3657. https://doi.org/10.1016/j.artmed.2020.101935.

64. Tizhoosh H., Pantanowitz L. "Artificial Intelligence and Digital Pathology: Challenges and Opportunities." *J Pathol Inform*. 2018;9:38. Published 2018 Nov 14. doi:10.4103/jpi.jpi_53_18.

65. Jiang Y., Yang M., Wang S., et al. "Emerging role of deep learning-based artificial intelligence in tumor pathology." *Cancer Commun (Lond)*. 2020; 40(4):154-166. doi:10.1002/cac2.12012.

66. Samek W., Wiegand T., Müller K-R. "Explainable artificial intelligence: understanding, visualizing and interpreting deep learning models." *arXiv Preprint*. arXiv:170808296 2017.

67. Regitnig P., Müller H., Holzinger A. (2020) Expectations of Artificial Intelligence for Pathology. In: Holzinger A., Goebel R., Mengel M., Müller H. (eds) *Artificial Intelligence and Machine Learning for Digital Pathology. Lecture Notes in Computer Science, vol 12090*. Springer, Cham. https://doi.org/10.1007/978-3-030-50402-1_1.

68. Mukhopadhyay S., Feldman M., Abels E. et al. "Whole slide imaging versus microscopy for primary diagnosis in surgical pathology: a multicenter blinded randomized noninferiority study of 1992 cases." Am. J. Surg. Pathol., 42 (2018), pp. 39-52. doi: 10.1097/ PAS.0000000000000948.

69. U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Memorandum–K190332, (n.d.). https://www.accessdata.fda.gov/cdrh_docs/reviews/ K190332.pdf.

70. Steiner D., Chen P., Mermel C. "Closing the translation gap: AI applications in digital pathology." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1875, Issue 1, 2021, 188452, ISSN 0304-419X.